Results 171 to 180 of about 91,018 (321)

Mechanism of salt-mediated inhibition of lipoprotein lipase

open access: yesJournal of Lipid Research, 1976
The activity of lipoprotein lipase isolated from rat postheparin plasma has been determined with synthetic lipids, in the presence and absence of apoprotein of the natural substrate very low density lipoprotein, as a function of medium ion-pair ...
C J Fielding, P E Fielding
doaj  

The Association of Adipokines and Myokines in the Blood of Obese Children and Adolescents with Lipoprotein Lipase rs328 Gene Variants. [PDF]

open access: yesJ Obes, 2023
Shestopalov AV   +10 more
europepmc   +1 more source

Variants in ANGPTL4 and the Risk of Coronary Artery Disease [PDF]

open access: yes, 2016
Doria, Alessandro   +2 more
core   +1 more source

Impact of Fatty Acid Carbon Chain Length and Protein Composition on Physicochemical and Digestive Properties of MFGM Contained Emulsions

open access: yesFood Science &Nutrition, Volume 13, Issue 7, July 2025.
Emulsions prepared by OPO (long‐chain fatty acids) exhibited the largest average particle size and greater stability compared to those with medium‐chain fat (coconut oil) and ultra‐long‐chain fat (DHA algae oil). When whey protein and casein were added in a 6:4 ratio, the effect of fatty acid carbon chain length on the average particle and the ...
Yanchen Liu   +5 more
wiley   +1 more source

The lipoprotein lipase of mammary gland and the correlation of its activity to lactation

open access: yesJournal of Lipid Research, 1963
The concentration of lipoprotein lipase of guinea pig mammary gland increases markedly just prior to parturition, reaching a maximal level within 2 hr post-partum.
O.W. McBride, Edward D. Korn
doaj  

Pharmacokinetics and Safety of Fenofibrate in Participants with Mild Hepatic Impairment or with Advanced Fibrosis due to Metabolic‐Associated Fatty Liver Disease

open access: yesThe Journal of Clinical Pharmacology, Volume 65, Issue 7, Page 850-859, July 2025.
Abstract Fenofibrate is contraindicated in patients with advanced hepatic fibrosis due to limited clinical data. We evaluated the pharmacokinetics and safety of fenofibrate in participants with mild hepatic impairment (phase 1 study) or advanced fibrosis due to metabolic‐associated fatty liver disease (MAFLD; phase 2a study).
Islam R. Younis   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy